6
Phase 2–4 trials
MASH / liver disease · Live ClinicalTrials.gov data
Efruxifermin clinical trial pipeline
ClinicalTrials.gov lists 6 phase 2–4 trials for efruxifermin, 2 of them actively recruiting. The next phase 3 primary completion among them is expected Feb 2030. Refreshed daily — add up to four competitors to compare pipelines side by side.
3
Phase 3 trials
2
Actively recruiting
Feb 2030
Next phase 3 primary completion
4,920
Participants across trials
Akero Therapeutics, Inc
Lead sponsor by trial count
efruxifermin (6)4 active2019–2034
efruxifermin
'19
'21
'23
'25
'27
'29
'31
'33
efruxifermin
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)P2
HarmonyP2
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)P2
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)P3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisP3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHP3
Upcoming readouts
2 ahead · efruxifermin
Select a trial to load its full ClinicalTrials.gov record.
Key efruxifermin trials
Top 6 of the 6 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06528314 | A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Recruiting | Feb 2030 |
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic D… | Phase 3 | Recruiting | Feb 2033 |
| NCT06161571 | A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/… | Phase 3 | Active, not recruiting | Mar 2026 |
| NCT05039450 | A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Sym… | Phase 2 | Active, not recruiting | Aug 2023 |
| NCT03976401 | A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Feb 2021 |
| NCT04767529 | Harmony — A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (… | Phase 2 | Completed | May 2024 |
Related drug pipelines
FAQ
- How many clinical trials are running for efruxifermin?
- ClinicalTrials.gov currently lists 6 phase 2–4 efruxifermin trials: 3 phase 2, 3 phase 3, and 0 phase 4. 2 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare efruxifermin against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.